In this article, we will discuss the 12 High Growth Large Cap Stocks to Buy Now. BlackRock highlighted that its portfolio ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Overview: ALSO Holding AG is a technology services provider for the ICT industry, operating in Switzerland, Germany, the Netherlands, Poland, and internationally with a market capitalization of ...

Overview: Bolloré SE operates in transportation and logistics, communications, and industry sectors across various regions including France, Europe, the Americas, Asia, Oceania, and Africa with a ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

In the wake of recent U.S. elections, global markets have experienced notable shifts, with major benchmarks like the S&P 500 and Russell 2000 showing impressive gains as investors anticipate potential ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of ...

In recent weeks, global markets have experienced significant movements, with U.S. stocks rallying on growth and tax hopes ...

Despite positive trial data, Sarepta Therapeutics has decided to stop the clinical development of SRP-5051 (vesleteplirsen), ...